Clinical Trial Update: A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating epoetin alfa to reduce perioperative blood transfusions in hip replacement surgery has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: Janssen-Ortho Inc., Canada | Conditions: Anemia, Blood Transfusion | Phase 3 | Status: WITHDRAWN